Servier Chooses Tripos as Chemistry Partner in Search for Drugs
News Sep 08, 2005
Tripos, Inc. and Servier have announced that they will work together to identify potential drugs. Servier identified and subsequently validated therapeutic compounds from Tripos' LeadQuest® compound collection.
Based on these results, Servier has chosen to partner with Tripos to further design and synthesize compounds for potential drug development. Tripos will employ its ChemSpace® and LeadHopping® proprietary technologies and integrated knowledge-driven chemistry processes to identify additional chemistries against the same targets.
Tripos' ChemSpace technology is used to identify similar but distinct chemical entities, while its LeadHopping technology helps scientists navigate the patent space.
"Servier has earned an impressive reputation for research, and to be chosen as their partner is an honor for our Tripos team," said Dr. Mark Allen, senior vice president and managing director of Tripos Discovery Research, Ltd.
He adds, "By applying our proprietary chemistry processes, Servier will be able to identify potential leads much sooner, therefore accelerating the research process. We hope the success we generate through this drug discovery project will lay the foundation for future Tripos and Servier partnerships and developments."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE